• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Additional aromatase inhibitor may improve endometrial cancer chemotherapy effectiveness

byMonica ParksandDavid Wang
February 3, 2015
in Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a phase II trial of 35 women with advanced endometrial cancer, combination therapy with aromatase inhibitor (letrozole) and mTOR inhibitor (everolimus) demonstrated a high clinical benefit rate.

Evidence Rating Level: 2 (Good)

Study Rundown: Endometrial cancer (EC) is the most common gynecological malignancy in the United States with over 52 000 cases diagnosed in 2014. Previous studies have noted an association between dysregulation of the phosphoinositol-3 kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway with poorer prognosis in EC patients. Estrogen receptor (ER) signaling have been shown to cross-regulate the PI3K/mTOR signaling pathway and may provide a potential target for mTOR signaling inhibition. The purpose of this phase II clinical trial was to evaluate the response of a combination therapy of an aromatase inhibitor (letrozole) and PI3K/mTOR inhibitor (everolimus) in patients with recurrent EC. Overall, 35 patients with recurrent/metastatic EC were treated with the combination therapy. At the conclusion of the trial, the combination treatment demonstrated a clinical response rate of 40% at 16 weeks, as measured by prolonged stable disease. The safety profile of this combination was excellent as there were no patients that discontinued treatment due to toxicity. The most significant predictor of response were patients with endometrioid histology. The results of this trial support the use of everolimus and letrozole in women with advanced endometrioid EC. However, this was only a phase II trial with a small sample size; additional larger randomized controlled trials are required to accurately describe the efficacy of this combination treatment.

Click to read the study in JCO

Relevant Reading: A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.

In-Depth [prospective cohort]: This clinical trial was a phase II, open-labelled, multi-centered trial to determine the effectiveness of the combination therapy of letrozole and everolimus in patients with advanced EC. Overall, 35 patients (median age 62 years; range: 24-82 years) with progressive or recurrent EC were recruited to receive daily doses of oral letrozole and everolimus for 4 week cycles. The primary end point was clinical benefit rate (CBR), defined as complete response, partial response, or stable disease for 16 weeks or more. After a median follow-up of 14 months, the CBR was 40% (14 patients) at 16 weeks with a median number of cycles of 15 (range: 7-29 cycles). Twenty percent of patients discontinued treatment after prolonged complete response. The most common side-effects included fatigue (74%), hypercholesterolemia (71%), and mucositis (66%); no patients discontinued treatment due to adverse events. The median overall survival time was 14 months (95% CI: 9.5 to 24.4 months). Patients with endometrioid histology demonstrated significantly increased CBR compared to patients with serous histology (37.5% vs 0%; p<0.0092).

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

RELATED REPORTS

Endovaginal ultrasound highly sensitive screen for endometrial cancer [Classics Series]

#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers

#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: aromatase inhibitorendometrial cancer
Previous Post

2 Minute Medicine Rewind January 26 – February 1, 2015

Next Post

Increasing proxy-reported pain at end-of-life from 1998-2010

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Chronic Disease

Endovaginal ultrasound highly sensitive screen for endometrial cancer [Classics Series]

August 9, 2022
#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
StudyGraphics

#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers

August 2, 2022
#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage
StudyGraphics

#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage

July 19, 2022
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in  premenopausal women with ER+ breast cancer and ovarian suppression
StudyGraphics

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression

May 3, 2022
Next Post
Increasing proxy-reported pain at end-of-life from 1998-2010

Increasing proxy-reported pain at end-of-life from 1998-2010

Vaccines for predicted influenza strains may provide wide protection [PreClinical]

Oseltamivir (Tamiflu) reduces duration of influenza symptoms, respiratory complications, and hospital admissions

Smokeless tobacco use in children has not changed

Financial incentives improve smoking cessation rates in pregnant women

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Ciprofol comparable to propofol for general anesthesia induction for gynecological surgery
  • Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy
  • Type of compensation model influences gender pay gap in primary care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.